Investor Relations

About Tectonic Therapeutic


Tectonic has developed a proprietary technology platform called GEODe™ to enable the discovery and development of GPCR-targeted biologic medicines that can modify the course of disease, by addressing challenges that have limited the pace of innovation in this field. Tectonic’s TX45 Fc-relaxin fusion protein is a potential best-in-class agent, resulting from protein engineering efforts to overcome limitations associated with the natural human hormone and achieve both optimal in vitro (biophysical and developability), as well as in vivo (pharmacokinetic and pharmacodynamic, or “PK/PD”) properties. Tectonic is leveraging relaxin’s vasodilatory and anti-fibrotic properties with the goal of improving treatment outcomes for patients with Group 2 pulmonary hypertension. Tectonic is headquartered in Watertown, Massachusetts. Learn more at www.tectonictx.com and follow us @TectonicTx.

Events & Presentations

Stock Chart

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Our News Latest press releases

Jun 20, 2024

Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million

Tectonic will be focused on advancing a pipeline of novel G-protein-coupled receptor (“GPCR”) targeted biologic therapies, including the lead program, TX45, a Fc-relaxin fusion TX45 is currently being evaluated in Phase 1a/1b clinical trials as a potential treatment for Group 2 Pulmonary

Read More

Jun 03, 2024

Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer

WATERTOWN, Mass.--(BUSINESS WIRE)--Tectonic Therapeutic, Inc. (“Tectonic”), a privately-held biotechnology company developing GPCR (G-protein coupled receptor)-targeted therapeutic proteins, today announced the appointment of Daniel Lochner as Chief Financial Officer of Tectonic.

Read More

Mar 26, 2024

Tectonic Therapeutic Initiates Phase 1B Study for TX45 in Group 2 Pulmonary Hypertension in Patients with Preserved Ejection Fraction Heart Failure

Study to evaluate TX45 impact on cardiopulmonary hemodynamics in patients with Group 2 Pulmonary Hypertension, a patient population in urgent need of novel therapies TX45 clinical program advancing on track based on promising initial Phase 1A data; confirmatory Phase 1A data expected mid-2024 and

Read More

See All

Investors & Media Sign up for
Email Alerts

We’ll keep you connected to the latest news about Tectonic Therapeutic’s research and pipeline.

Contact Us

Tectonic Therapeutic

Copyright © 2024 Tectonic Therapeutic